cells was determined by qPCR, following vehicle or P5091 treatment (25 μM) for 24 h, and normalized against expression of GAPDH. The values are the mean +/− SD of three independent experiments.
Supplementary Figure 2:
The addition of P5091 to olaparib shows dose-dependent cytotoxic effects in prostate cancer cell lines. LNCaP, PC3 and 22Rv1 cells were seeded in 96-well plates and 24 h later exposed to olaparib at the indicated doses, together with P5091 (at a fixed dose of 2.5 μM) in presence or absence of the pan-caspase inhibitor Z-VAD-FMK (20 μM) for 72 h, and analysed for viability by using a modified 3-(4,5-dimethylthiazole-2-yl)-2-5-diphenyltetrazolium bromide assay, CellTiter 96 Aqueous One Solution assay (Promega), as 50% inhibitory concentration (IC50) values. The values are presented as mean standard deviation of three independent experiments. Surviving fraction of LNCaP, PC3 and 22Rv1 cells are shown, compared to olaparib treated cells. 
Supplementary

